Abstract
The European Respiratory Society (ERS) celebrated the return of an in-person meeting in Barcelona, Spain, after two years of virtual congresses. The congress programme was replete with symposia, skills workshops and abstract presentations from all 14 assemblies, encompassing over 3000 abstracts presented in the form of thematic poster discussion and oral presentations. In this article, highlights from this year's congress (including that from thematic poster sessions, oral presentations and symposia from keynote speakers), presented by Assembly 5: Airway diseases, Asthma, COPD and Chronic Cough, are reviewed by Early Career Members and experts in the field, with the aim of presenting key recent findings in the field.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Dr Bossios A declares honoraria for Advisory Board Meetings from GSK, AstraZeneca, Teva, Novartis and Sanofi, is a member of the steering committee of SHARP, secretary of Assembly 5 (airway diseases, asthma, COPD and chronic cough) European Respiratory Society and vice-chair of Nordic Severe Asthma Network (NSAN). Dr Braunstahl G-J reports attending advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim and Sanofi, honoraria from Novartis, AstraZeneca, Chiesi, GlaxoSmithKline, Teva and ALK Abello, participated in research with GlaxoSmithKline, Chiesi, AstraZeneca, ALK Abello, Novartis and Teva and attended international conferences with Novartis and Teva, Dr Gotera C declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and GlaxoSmithKline, Dr Pobeha P declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and Angeliny, is secretary of assembly 05.02 (monitoring airway disease) European Respiratory Society and member of steering committee Slovak respiratory society and Slovak sleep medicine society. Dr Portacci A declares honoraria for Astrazeneca; GlaxoSmithKline; Chiesi and Sanofi. Prof. Snelgrove R declares grants from The Wellcome Trust. Prof Uller L reports payment or honoraria from AstraZeneca for lectures, presentations, speakers bureaus, manuscript writing or educational events, Prof Dr Usmani O reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer ingelheim, grants and personal fees from Chiesi, grants and personal fees from Glaxosmithkline, personal fees from Napp, personal fees from Mundipharma, personal fees from Sandoz, personal fees from Takeda, grants from Edmond pharma, personal fees from Cipla, personal fees from Covis, personal fees from Novartis, personal fees from Mereo biopharma, personal fees from Orion, personal fees from Menarini, personal fees from Ucb, personal fees from Trudell medical, personal fees from Deva, personal fees from Kamada, personal fees from Covis, personal fees from Kyorin, outside the submitted work and is chair of Assembly 5 (airway diseases, asthma, COPD and chronic cough) European Respiratory Society. Miss Beech A, Prof Ricciardolo F L.M, Dr Herrero-Cortina B, Dr Mathioudakis A.G, and Dr Anannths, S declare no conflicts of interest.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©The authors 2023
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
